Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25108983 | 1.00 | TSHR (0.50) | TSHRHPGDHTTSMN1; SMN2GLP1R | |
| SCHEMBL25110213 | 1.00 | TSHR (0.50) | TSHRHPGDHTTSMN1; SMN2GLP1R | |
| SCHEMBL25109361 | 0.88 | GLP1R (0.41) | GLP1RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25109437 | 0.88 | GLP1R (0.41) | GLP1RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25109388 | 0.88 | GLP1R (0.41) | GLP1RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25109438 | 0.87 | EPHX2 (0.42) | GLP1RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25108979 | 0.85 | TSHR (0.62) | TSHRHPGDHTTSMN1; SMN2MEN1 | |
| SCHEMBL25108952 | 0.85 | TSHR (0.62) | TSHRHPGDHTTSMN1; SMN2MEN1 | |
| SCHEMBL25108941 | 0.85 | TSHR (0.62) | TSHRHPGDHTTSMN1; SMN2MEN1 | |
| SCHEMBL18101018 | 0.85 | GLP1R (0.48) | TSHRGLP1RMEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | TSHR 3796/4885HPGD 4236/4885HTT 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.